The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
10 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $8,038,615 in first-year total cost, median $625,038.
Most frequent study sections
- Special Emphasis Panel[ZRG1 MCST-U (55)]10
Most frequent institutions
- BRIGHAM AND WOMEN'S HOSPITAL1
- JOHNS HOPKINS UNIVERSITY1
- MASSACHUSETTS GENERAL HOSPITAL1
- OHIO STATE UNIVERSITY1
- UNIVERSITY OF ALABAMA AT BIRMINGHAM1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | Nanotechnology enabled quantitative imaging of dendritic cell anti-cancer vaccines1R01CA298804-01A1 | MITCHELL, DUANE A.RINALDI-RAMOS, CARLOS M | UNIVERSITY OF FLORIDA, FL | $2,628,974 | ZRG1 |
| 2025 | Expanding the therapeutic window of chemoradiation through radiation-responsive nanoparticle drug depots1R01CA293888-01A1 | MILLER, MILES ASCHUEMANN, JAN PATRICK OSCAR | MASSACHUSETTS GENERAL HOSPITAL, MA | $644,034 | ZRG1 |
| 2025 | Engineered Lipid Nanoparticles and Microgel Matrix to Program Th1/Th2 Immune Response1R01CA293906-01A1 | MAO, HAI-QUAN | JOHNS HOPKINS UNIVERSITY, MD | $630,781 | ZRG1 |
| 2025 | Novel approach to modulate the TME on-demand with therapeutic peptides and proteins.1R01CA298815-01A1 | LAM, KIT S | UNIVERSITY OF CALIFORNIA AT DAVIS, CA | $615,399 | ZRG1 |
| 2024 | Combinatorial application of nanoscale technologies to target a novel mechanism of immune evasion by cancer cells1R01CA293908-01 | SENGUPTA, SHILADITYA | BRIGHAM AND WOMEN'S HOSPITAL, MA | $690,825 | ZRG1 |
| 2024 | Development of a New Multiplexed Imaging Strategy for Immunoprofiling using Raman-Active Nanoparticles1R01CA293950-01 | MALLICK, PARAG KUMARZAVALETA, CRISTINA L. | UNIVERSITY OF SOUTHERN CALIFORNIA, CA | $643,522 | ZRG1 |
| 2024 | CPMV-Polymer Devices to Enhance the Outcomes of Intratumoral Immunotherapy1R01CA293936-01 | POKORSKI, JONATHAN KYLESTEINMETZ, NICOLE FRANZISKA | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $619,294 | ZRG1 |
| 2024 | The resurgence of antibody-drug conjugates via PMPC-polymer engineering1R01CA293907-01 | KAMATA, MASAKAZU | UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL | $585,228 | ZRG1 |
| 2024 | Mechanism and approach to inactivate mutant KRAS of lung metastatic colon cancer by RNA-ligand-displaying exosome to co-deliver dCas9--gRNA ribonucleoprotein complex and KRAS siRNA1R01CA293945-01 | GUO, BINGUO, PEIXUANRYCHAHOU, PIOTR | OHIO STATE UNIVERSITY, OH | $497,002 | ZRG1 |
| 2024 | TLR Agonist Nano-Immune Therapy for Peritoneal Metastases1R01CA293942-01 | SERDA, RITA ELENA | UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR, NM | $483,556 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.